Physician's Weekly Article - Agent Treats Hereditary Angioedema

March 15, 2010
Vol. XXVII, No. 11

Home

Past Issues

Back to Phys Weekly

Through The Pipeline

View Printable Page

Agent Treats Hereditary Angioedema

       Ecallantide (Kalbitor, Dyax Corp.) was approved by the FDA to treat fluid buildup that can occur in people who have hereditary angioedema (HAE). The liquid drug is injected under the skin for patients aged 16 and older who experience HAE attacks. It should only be administered by clinicians with appropriate medical support to manage anaphylaxis.

      Source: FDA and Dyax Corp.

REFERENCE LINKS:

For more on the approval, go to www.fda.gov/NewsEvents or to http://investor.dyax.com.

To get Physician's Weekly posted in your hospital, click HERE

PW Archives \| Past Issues \| Register \| Contact Us \| Search Archive \|
Back To Top	© 2010 Physician’s Weekly, LLC Web design and development by Spindustry Interactive™